Skip to main content

RDY

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

RDY Price
Price Chart

Forward-looking statistics

Beta
0.42
Risk
22.26%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

They are an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees24K
Market cap$11.9B

Fundamentals

Enterprise value$60.2M
Revenue$3.8B
Revenue per employee—
Profit margin17.37%
Debt to equity13.87

Security info

ExchangeNyse American
Type of shareADR
Earnings per share (EPS)$0.79
Dividend per share$1.92
Revenue per share$65.27
Avg trading volume (30 day)$23M
Avg trading volume (10 day)$20M
Put-call ratio—

Macro factor sensitivity

Growth+1.8
Credit+1.2
Liquidity-0.9
Inflation+0.4
Commodities-0.2
Interest Rates-0.7

Valuation

Dividend yield12.61%
PEG Ratio17.33
Price to sales0.04
P/E Ratio17.33
Enterprise Value to Revenue0.02
Price to book0.04

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend dayJuly 30, 2024

News

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.

Benzinga (June 5, 2025)
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

Zacks Investment Research (June 5, 2025)
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans to expand its diabetes and obesity drug offerings amid increasing competition.

CNBC International TV (May 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free